CD19 and B-cell non-Hodgkin lymphoma: A recent Phase II trial (NCT04576721) is evaluating the combination of anti-PD-1 therapy (pembrolizumab), CD19 CAR-T cells, and a ferroptosis inducer (erastin) in patients with relapsed/refractory B-cell lymphomas.